

## CURRICULUM VITAE

**ALESSIA FORNONI**

---

1. **DATE:** Jan 2015

### I. PERSONAL

2. **Name:** Alessia Fornoni, M.D., Ph.D., FASN  
3. **Home phone:** 305-665-9999  
4. **Office phone:** 305-243-6558  
5. **Home address:** 7745 SW 54<sup>th</sup> Ave, Miami, FL, 33143  
6. **Current Academic Rank:** Associate Professor  
6a. **Current Track of Appointment:** Tenured  
7. **Primary Department:** Medicine  
8. **Secondary or Joint Appointments:**  
1) Diabetes Research Institute (2005-2012)  
2) Molecular and Cellular Pharmacology (2010-present)  
9. **Citizenship:** USA  
10. **Visa:** N/A

### II. HIGHER EDUCATION

#### 11. Institutional

- 10/1989-07/1995 School of Medicine, University of Pavia, Italy, M.D.  
11/1995-01/2000 Medical Pharmacology, University of Pavia, Italy, Ph.D.

#### 12. Non-Institutional: N/A

- 10/1992-06/1995 Sub-Internship, University Hospital I.R.C.C.S., Policlinico San Matteo, Pavia, in Obstetrics, Surgery, Pediatrics, Internal Medicine and Emergency Medicine  
07/1995-04/1998 Intern, Nephrology and Dialysis Unit, University Hospital Policlinico San Matteo, Pavia, Italy

#### 13. Certifications and licensure

- 09/29/2000 USMLE Step I  
07/13/2000 USMLE Step II  
03/12/2001 Clinical Skills Assessment  
05/04/2001 ECFMG Certification # 0-617-452-8  
2004-2014 Board Certification in Internal Medicine  
2005 Board Certification in Nephrology

### III. EXPERIENCE

#### 14. Academic

- 04/2001-06/2002 **Instructor**, Vascular Biology Institute, University of Miami. Mentors: Liliane J. Striker, MD and Gary E. Striker, MD. Projects included the role of microsatellite instability and of bone marrow derived stem cells in the pathogenesis of glomerulosclerosis. 20-30% of the time is dedicated to train young fellows.

07/2005-05/2009 **Assistant Professor of Clinical Medicine**, Division of Nephrology and Hypertension and Diabetes Research Institute, University of Miami School of Medicine.

06/2009-05/2012 **Assistant Professor of Medicine**, Division of Nephrology and Hypertension and Diabetes Research Institute, University of Miami School of Medicine.

08/2009-present **Director**, Diabetic Nephropathy Clinic

02/2010-present **Assistant Professor of Molecular and Cellular Pharmacology**, University of Miami School of Medicine.

06/2012-present **Associate Professor of Medicine**, University of Miami School of Medicine.

12/2012-08/2013 **Associate Director**, The Peggy and Harold Katz Family Drug Discovery Center.

08/2013-present **Director and Chair**, The Peggy and Harold Katz Family Drug Discovery Institute.

### 15. Hospital Appointments

06/2002-06/2004 **House-staff Physician** in Internal Medicine, Jackson Memorial Hospital, Miami.

07/2004-06/2005 **House-staff Physician** in Nephrology, Jackson Memorial Hospital, Miami

10/2005-present Miami Veterans Affairs Medical Center, consultant (without compensation)

06/2005-present Jackson Memorial Hospital, staff

06/2005-present University of Miami Hospital and Clinics, staff

### 16. Non-Academic

04/1998-04/2000 **Research Associate**, Renal Cell Biology Laboratory, University of Miami. Mentors: Liliame J. Striker, MD and Gary E. Striker, MD. Projects included investigation of pharmacotherapy, growth factors and hormones on isolated glomerular cells, vascular smooth muscle cells and bone cells. Techniques applied include: Isolation and propagation of glomerular cells, standard and competitive RT-PCR, gene cloning, mammalian cell transfection, ELISA, western blotting, zymography, reverse zymography, histochemistry and light microscopy

08/1996 Substitute **Primary Care Physician**, Ardesio (BG), Italy

08/1997 Substitute **Primary Care Physician**, Ardesio (BG), Italy

08/2013-12/2013 **Global Head of Discovery** in Cardiovascular and Metabolism, Hoffman-La Roche, Basel, Switzerland.

10/2013-present **Vice-President and CSO**, L&F Health LLC

### 17. Military: N/A

## IV. PUBLICATIONS

### 18. Book chapters

1. Riser, BL, **Fornoni A** and Karoor S. CCN2 (Connective Tissue Growth Factor) In the Pathogenesis of Diabetic Nephropathy: a target for therapeutic interventions. In: The diabetic kidney. Publisher: Humana Press, Editor: P. Cortes and C.E.Morgensen. Chapter 10:175, 2006
2. **Fornoni A**, Carlos L, Raij L Diabetic Nephropathy. In: The aging Kidney in Health and Disease. Editors: Macias-Nunez JF, Cameron JS, Oreopoulos G. Springer Publisher, Norwell, MA, Chapter 18: 329-346, 2008
3. Merscher S, Lenz O, **Fornoni A**. Podocytopathy in Diabetes: an Endocrine Disorder. In: Podocytopathy. Series Editor: C Ronco. Volume Editors: Zhi-Hong Liu, John C. He. Publisher: Karger. Contributions to Nephrology, Volume 183: 157-173, 2014.

### 19. Juried or refereed journal articles

1. Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Bellingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolori F, Murer L, Reiser J, **Fornoni A**, Ghiggeri GM. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol, 2015, E-pub.
2. Coward R, **Fornoni A**. Insulin signaling: implication for podocyte biology in diabetic kidney disease. Curr Opin Nephrol Hypertens, 24: 104-110, 2015
3. Yoo TH, Pedigo EC, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq, Faul C, Li J, Kretzler M, Nelson RG, Lehto M, Forsblom C, Groop P-H, Reiser J, Burke GW, **Fornoni A**, Merscher S. SMPDL3b expression levels determine podocyte injury phenotypes in glomerular disease. 2015, 26:133-147.
4. Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, **Fornoni A**, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med, 6:256ra136, 2014.
5. Merscher S, **Fornoni A**. Podocyte pathology and nephropathy-sphingolipids in glomerular diseases. Frontiers in Endocrinology, 5:1-11, 2014.
6. **Fornoni A**, Merscher S, Kopp JB. Lipid biology of the podocyte: new perspectives offer new opportunities. Nature Review Nephrology, 10:379-88, 2014.
7. Lipshultz SE, Chandar JJ, Rusconi PG, **Fornoni A**, Abitbol CL, Burke lii GW, Zilleruelo GE, Pham SM, Perez EE, Karnik R, Hunter JA, Dauphin DD, Wilkinson JD. Issues in solid-organ transplantation in children: translational research from bench to bedside. Clinics. 2014, 69

Suppl 1:55-72.

8. Reiser J, **Fornoni A**. Rituximab, a boot to protect the foot. *J Am Soc Nephrol*, 25:647-8, 2014.
9. Burke GW, Chang JW, Pardo V, Sageshima J, Chen L, Ciancio G, Tsai HL, and **Fornoni A**. Podocyte foot process effacement in postreperfusion allograft biopsies. *Transplantation*, 2014, 97:e38-9.
10. Berneman-Zeitouni D, Molakandov K, Elgart M, Mor E, **Fornoni A**, Domínguez MR, Kerr-Conte J, Ott M, Meivar-Levy I, Ferber S, The temporal and hierarchical control of transcription factors-induced liver to pancreas transdifferentiation. *PlosONE*, 9:e87812, 2014.
11. Kistler,AD, Caicedo A, Abdulreda MH, Faul C, Kerjaschki D, Berggren PO, Reiser J and **Fornoni A**. In vivo imaging of kidney glomeruli transplanted into the anterior chamber of the mouse eye. *Scientific Reports*, 4:3872, 2014.
12. Guzman J, Jauregui AN, Merscher-Gomez S, Maignel D, Muresan C, Mitrofanova A, Diez-Sampedro A, Szust J, Yoo TH, Villarreal R, Pedigo C, Molano RD, Johnson K, Kahn B, Hartleben B, Huber TB, Burke GW 3rd, Abel ED, Brosius FC, **Fornoni A**. Podocyte-specific GLUT4 deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy. *Diabetes*, 63:701-14, 2014.
13. Gonzalez Suarez ML, Thomas DB, Barisoni L, **Fornoni A**. Diabetic Nephropathy: is it time yet for routine kidney biopsy?. *World J Diabetes*, 4:245-255, 2013.
14. Yu C, **Fornoni A**, Weins A, Hakrroush S, Maignel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang J, Chen H, Oh J, Faul C, Arnaut A, Fiorina P, Gupta V, Greka A, Burke G, Mundel P. Abatacept As Therapy for B7-1 Positive Proteinuric Kidney Disease. *NEJM*, 369:2416-23, 2013.
15. Merscher-Gomez S, Guzman J, Pedigo CE, Lehto M, Aguillon-Prada R, Mendez A, Lassenius MI, Forsblom C, Yoo T, Villarreal R, Maignel D, Johnson K, Goldberg R, Nair V, Randolph A, Kretzler M, Nelson RG, Burke III GW, Groop P-H, **Fornoni A**. Cyclodextrin protects podocytes in diabetic kidney disease. *Diabetes*, 62:3817-27, 2013.
16. Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, **Fornoni A**, Burke G, Rabb H, Kakkad K, Reiser J, Estrella, MM. Podocyte effacement closely links to suPAR levels at time of post-transplant focal segmental glomerulosclerosis occurrence and improves with therapy. *Transplantation*, 96:649-56, 2013.
17. Ravani P, Ponticelli P, Siciliano C, **Fornoni A**, Magnasco A, Sica F, Bodria M, Caridi G, Wie C, Belinghieri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM. Use of Rituximab in Children with Steroid- and Calcineurin-Inhibitor-Dependent Idiopathic Nephrotic Syndrome. *Kidney International*, 84:1025-33, 2013.
18. Catanuto P, **Fornoni A**, Wu F, Burnstein K, Conti F, Lenzi A, and Elliot S. In vivo 17b-estradiol treatment contributes to podocyte actin stabilization. *Endocrinology*, 153:5888-95, 2012.
19. Ciancio G, Sageshima J, Chen L, Gaynor JJ, Hanson L, Tueros L, Brown R, Rivas J, Roth D, Kupin W, Guerra G, Mattiazzi A, **Fornoni A**, Pugliese A, Burke GW III. Rapamycin versus mycophenolate mofetil in simultaneous pancreas kidney (SPK) transplant recipients. *Am J Transpl*, 2:3363-76, 2012.

20. Jeon J, Leibiger I, Moede T, Walter B, Faul C, Maignel D, Villarreal R, Guzman J, Berggren PO, Mundel P, Ricordi C, Merscher-Gomez S, **Fornoni A**. Dynamin-mediated Nephric phosphorylation Regulates Glucose-stimulated Insulin Release in Pancreatic beta Cells. *Journal of Biological Chemistry*, 287:28932-42, 2012.
21. Chang J, Pardo V, Sageshima J, Chen L, Tsai HL, Reiser J, Wei C, Ciancio G, Burke WG III, **Fornoni A**. Podocyte Foot Process Effacement in Post-reperfusion Allograft Biopsies Correlates with Early Recurrence of Proteinuria in Focal Segmental Glomerulosclerosis. *Transplantation*, 93:1238-44, 2012.
22. Vodopivec D, Rubio JE, **Fornoni A** and Lenz O. An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review. *Case Reports in Medicine*, 2012:468452, 2012.
23. Hogan AR, Doni M, Molano RD, Ribeiro MM, Szeto A, Cobiauchi L, Zahr-Akrawi E, Molina J, **Fornoni A**, Mendez AJ, Ricordi C, Pastori, RL and Pileggi A. Beneficial Effects of Ischemic Preconditioning on Pancreas Cold Preservation. *Cell Transplantation*, 2012, E-pub.
24. Wei C, El Hindi S, Li J, **Fornoni A**, Goes N, Sageshima J, Maignel D, Karumanchi SA, Yap H-K, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating Urokinase Receptor as Cause for Focal Segmental Glomerulosclerosis. *Nature Medicine*, 17:952-60, 2011.
25. **Fornoni A**, Sageshima J, Wei, C, Merscher-Gomez S, Aguilon-Prada R, Jauregui AN, Li J, Mattiazzi, A, Ciancio G, Chen L, Zilleruel G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J and Burke III GW. Podocytes are a direct target of rituximab in recurrent focal segmental glomerulosclerosis. *Science Translational Medicine*, 3:85ra46, 2011.
26. Gödel M, Hartleben B, Herbach N, Liu S, Zschidrich S, Lu S, Debreczeni-Mór A, Lindenmeyer MT, Rastaldi MP, Hartleben G, Wiech T, **Fornoni A**, Nelson RG, Kretzler M, Wanke R, Pavenstädt H, Kerjaschki D, Cohen CD, Hall MN, Rüegg MA, Inoki K, Walz G, and Huber TB. Role of mTOR for podocyte function and diabetic nephropathy progression in humans and mice. *Journal of Clinical Investigation*, 121:2197-209, 2011
27. Diez-Sampedro A, Lenz O, **Fornoni A**. Podocytopathy in diabetes: a metabolic and endocrine disorder. *American Journal of Kidney Disease*, 58:637-646, 2011.
28. Lenz O, **Fornoni A**. Proteinuria in diabetes: an endocrine disease? *Current Diabetes Reviews*. 7: 1-2, 2011
29. **Fornoni A**. Podocytes, proteinuria and Insulin Resistance. *New England Journal of Medicine*, 363:2068-2069, 2010
30. **Fornoni A**, Jeon J, Varona-Santos JL, Cobiauchi L, Jauregui A, Inverardi L, Mandic SA, Bark C, Johnson K, McNamara G, Pileggi A, Molano RD, Reiser J, Tryggvason K, Kerjaschki D, Berggren PO, Mundel P and Ricordi C. Nephric is expressed on the surface of insulin vesicles and facilitates glucose stimulated insulin release. *Diabetes*, 59:190-199, 2010
31. Ortega LM, **Fornoni A**. Role of cytokines in the pathogenesis of acute and chronic kidney disease, glomerulonephritis, and end-stage kidney disease. *International Journal of Interferon, Cytokine and Mediator Research*, 2: 1-14, 2010

32. Lenz, O, Sancassani, R., Bottino, C., **Fornoni, A.** Reversible bone pain and symmetric bone scan uptake in a dialysis patient treated with cinacalcet: a case report. *Journal of Medical Case Reports*: 4,191, 2010
33. Yamamoto T, Mita A, Ricordi C, Messinger S, Miki A, Sakuma Y, Timoneri F, Barker S, **Fornoni A**, Molano RD, Inverardi L, Pileggi A, Ichii H, Prolactin Supplementation to Culture Medium Improves Beta-Cell Survival. *Transplantation*, 89:1328-35, 2010
34. Takacs P, Gualtieri M, Nassiri M, Candiotti K, **Fornoni A**, Medina CA. Differential expression of smooth muscle regulatory proteins in the uterosacral ligaments of women with uterine prolapse. *American Journal of Obstetrics and Gynecology*, 202:620.e1-5, 2010
35. Ijaz A, Tejada T, Catanuto P, Xia X, Elliot SJ, Lenz O, Saenz MOS, Jauregui A, Molano RD, Pileggi A, Ricordi C and **Fornoni A.** C-jun N Terminal Kinase (JNK) Inhibition Improves Insulin Sensitivity but worsens Albuminuria in Experimental Diabetes. *Kidney International*, 75:381-388, 2009.
36. Jauregui A, Mundel P, Mintz D, **Fornoni A.** Role of insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria in diabetic nephropathy. *Current Opinion in Nephrology and Hypertension*, 18:539-545, 2009
37. Pileggi A, Ribeiro MM, Hogan AR, Molano RD, Embury JE, Ichii H, Cobianchi L, **Fornoni A**, Ricordi C, Pastori RL. Effects of pancreas cold ischemia on islet function and quality. *Transplantation Proceedings*, 41:1808-9, 2009
38. Takacs P, Gualtieri M, Nassiri M, Candiotti K, **Fornoni A**, Medina CA. Caldesmon expression is decreased in women with anterior vaginal wall prolapse: a pilot study. *Int Urogynecological Journal of Pelvic Floor Dysfunction*, 20: 985-990, 2009
39. Pileggi A, Ribeiro MM, Hogan AR, Molano RD, Cobianchi L, Ichii H, Embury J, Inverardi L, **Fornoni A**, Ricordi C and Pastori RL. Impact of Pancreatic Cold Preservation on Islet Recovery and Function. *Transplantation*, 87: 1442-1450, 2009
40. Catanuto P, Doublier S, **Fornoni A**, Lupia E, Berho M, Striker GE, Xia X, Karl M, Elliot SJ. 17 $\beta$ -estradiol and Tamoxifen upregulate estrogen receptor  $\beta$  and regulate podocyte signaling pathways in a model of type 2 diabetes. *Kidney International*, 75:1194-201, 2009
41. Takacs P, Nassiri M, Viciano A, Candiotti K, **Fornoni A**, Medina CA. Fibulin-5 expression is decreased in women with anterior vaginal wall prolapse. *Int Urogynecol J Pelvic Floor Dysfunct*, 20:207-11, 2009
42. Varona-Santos JL, Pileggi A, Molano RD, Sanabria NY, Ijaz A, Atsushi M, Ichii H, Pastori RL, Inverardi L, Ricordi C and **Fornoni A.** Opposite effect of c-jun N-terminal kinase (JNK)1 and JNK2 on pancreatic islets. *Diabetologia*, 51:2271-80, 2008
43. Tejada, T, Adeel I, Catanuto P, Varona-Santos J, Xia X, Sanchez P, Sanabria N, Lenz O, Elliot SJ, **Fornoni, A.** Failure to phosphorylate AKT in podocytes from diabetic mice with early nephropathy promotes cell death. *Kidney International*, 73: 1385-1393, 2008
44. **Fornoni A**, Pileggi A, Molano RD, Sanabria N, Tejada T, Gonzalez-Quintana J, Ichii H, Inverardi L, Ricordi C, Pastori RL. Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation. *Diabetologia*, 51:298-308, 2008

45. Lenz O, **Fornoni A**. Renin Angiotensin System Blockade and Diabetes: Moving the Adipose Organ from the Periphery to the Center. *Kidney International*, 74:851-853, 2008
46. **Fornoni A**, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. *Current Diabetes Review*, 4: 10-17, 2008
47. Cobianchi, L, **Fornoni, A**, Pileggi A, Molano, R.D., Sanabria, N.Y., Gonzalez-Quintana, J., Bocca, N., Marzorati, S., Zahr, E., Hogan, A.R., Ricordi, C., Inverardi, L. Riboflavin Inhibits IL-6 Expression and p-38 Activation in Islet Cells. *Cell Transplantation*, 17:559-66, 2008
48. Yamamoto T, Ricordi C, Mita A, Miki A, Sakuma Y, Molano RD, **Fornoni A**, Pileggi A, Inverardi L, Ichii H. beta-Cell Specific Cytoprotection by Prolactin on Human Islets. *Transplantation Proceedings* 40:382, 2008
49. **Fornoni A**, Cobianchi L, Sanabria NY, Pileggi A, Molano DR, Ichii H, Rosero S, Inverardi L, Ricordi C, Pastori RL. The L-isoform but not D-isoform of a JNK inhibitory peptide protects pancreatic  $\beta$ -cells. *Biochemical and Biophysical Research Communications*, 354:227-33, 2007
50. Tejada T, **Fornoni A**, Lenz O, Materson BJ. Combination therapy with Renin-Angiotensin system blocker s: will amlodipine replace hydrochlorothiazide? *Current Hypertension Reports*, 9:284-90, 2007
51. **Fornoni A**, Rosenzweig SA, Lenz O, Rivera A, Striker GE, Elliot SJ. Low IGFBP-2 expression is responsible for increased IRS-1 phosphorylation in mesangial cells from mice susceptible to glomerulosclerosis. *Endocrinology* 147:3547-54, 2006
52. De Freitas O, Lenz O, **Fornoni A**, Materson BJ. The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. *Vascular Health and Risk Management*, 2: 139-144, 2006
53. Tejada T, **Fornoni A**, Lenz O, Materson BJ. Nonpharmacologic therapy for hypertension: does it really work? *Current Cardiology Report*, 8: 418-424, 2006
54. Lenz O, **Fornoni A**, Contreras G. New directions in the management of severe lupus nephritis. *Minerva Urol Nefrol*, 58:29, 2006
55. Lenz O, **Fornoni A**. Chronic kidney disease care delivered by U.S. family medicine and internal medicine trainees: Results from an online survey. *BMC Medicine*, 4: 30, 2006
56. Lenz O, Sadhu S, **Fornoni A**, Asif A. Overutilization of central venous catheters in incident hemodialysis patients: reasons and potential resolution strategies. *Seminars in Dialysis*, 19:543-550, 2006
57. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, Nahar N, de La Cuesta C, Hurtado A, **Fornoni A**, Beltran-Garcia L, Asif A, Young L, Diego J, Zachariah M, Smith-Norwood B. Outcome in African American and Hispanics with lupus nephritis. *Kidney International*, 69:1846-51, 2006
58. **Fornoni, A.** and L. Raij, Metabolic Syndrome and Endothelial Dysfunction, *Current Hypertension Reports*, *Current Hypertension Reports*, 7:88-95, 2005.
59. Lenz O, Mekala DP, Patel DV, **Fornoni A**, Metz D, Roth D. Barriers to successful care for chronic kidney disease. *BMC Nephrology*, 27;6:11, 2005

60. Lenz, O., **Fornoni, A.** and Contreras G. Defining the Role of Mycophenolate Mofetil in the Treatment of Proliferative Lupus Nephritis. *Drugs* 65:2429-36, 2005
61. Karl, M., M. Potier, I.H. Schulman, A. Rivera, H. Werner, A. **Fornoni** and S.J. Elliot, Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells, *Endocrinology*, 146:889-900, 2005
62. Lenz, O., **Fornoni, A.** and Contreras G. Defining the Role of Mycophenolate Mofetil in the Treatment of Proliferative Lupus Nephritis. *Drugs* 65:2429-36, 2005
63. Vazquez-Padron, R.I., D. Lasko, S. Li, L. Louis, I.A. Pestana, M. Pang, C. Liotta, A. **Fornoni, A.** Aitouche and S.M. Pham, Aging Exacerbates Neointimal Formation, and Increases Proliferation and Reduces Susceptibility to Apoptosis of Vascular Smooth Muscle Cells in Mice, *Journal of Vascular Surgery*, 40:1199-1207, 2004
64. Zheng, F., F. Cornacchia, I. Schulman, A. Banerjee, Q.L. Cheng, M. Potier, A.R. Plati, M. Berho, S.J. Elliot, J. Li, **A. Fornoni**, Y.J. Zang, A. Zisman, L.J. Striker and G.E. Striker, Development of Albuminuria and Glomerular Lesions in Normoglycemic B6 Recipients of db/db Mice Bone Marrow: the Role of Mesangial Cell Progenitors, *Diabetes*, 53:2420-2427, 2004
65. **Fornoni, A.**, O. Lenz, L.J. Striker and G.E. Striker, Glucose Induces Clonal Selection and Reversible Dinucleotide Repeat Expansion in Mesangial Cells Isolated from Glomerulosclerosis-prone Mice, *Diabetes*, 52:2594-2602, 2003
66. **Fornoni, A.**, Y. Wang, O. Lenz, L.J. Striker and G.E. Striker, Association of a Decreased Number of d(CA) Repeats in the Matrix Metalloproteinase-9 Promoter with Glomerulosclerosis Susceptibility in Mice, *Journal of the American Society of Nephrology*, 13:2068-2076, 2002.
67. Zheng, F, **A. Fornoni**, S.J. Elliot, Y. Guan, M.D. Breyer, L.J. Striker and G.E. Striker, Upregulation of Type I Collagen by TGF-beta in Mesangial Cells is Blocked by PPAR-gamma Activation, *American Journal of Physiology Renal Physiology*, 282:F639-F648, 2002
68. **Fornoni, A.**, L.J. Striker, F. Zheng and G.E. Striker, Reversibility of Glucose-Induced Changes in Mesangial Cell Extracellular Matrix Depends on the Genetic Background, *Diabetes*, 51:499-505, 2002
69. Cornacchia, F., **A. Fornoni**, A.R. Plati, A. Thomas, Y. Wang, L. Inverardi, L.J. Striker and G.E. Striker, Glomerulosclerosis is Transmitted by Bone-Marrow Derived Mesangial Cell Progenitor. *Journal of Clinical Investigation*, 108:1649-56, 2001
70. **Fornoni, A.**, F. Cornacchia, G.A. Howard, B.A. Roos, G.E. Striker and L.J. Striker, Cyclosporin A Affects Extracellular Matrix Synthesis and Degradation by Mouse MC3T3-E1 Osteoblasts In Vitro, *Nephrology Dialysis Transplantation*, 16: 500-505, 2001
71. **Fornoni, A.**, H. Li, A. Foschi, G.E. Striker and L.J. Striker, Hepatocyte Growth Factor, but not Insulin-like Growth Factor I, Protects Podocytes Against Cyclosporin A-Induced Apoptosis, *American Journal of Pathology*, 158:275-280, 2001
72. **Fornoni, A.**, O. Lenz, I.Tack, M. Potier, S.J. Elliot, L.J. Striker and G.E. Striker, Matrix Accumulation in Mesangial Cells Exposed to Cyclosporine A Requires a Permissive Genetic Background, *Transplantation*, 70:587-593, 2000



73. Esposito, C., Semeraro L., Bellotti, N, Fasoli G, **Fornoni A**, Rampino T, Klersy C, Campana C, Gavazzi A, Vigano M and Dal Canton A, Risk Factors for Chronic Renal Dysfunction in Cardiac Allograft Patients, *Nephron*, 84:21-28, 2000
74. Esposito, C., **Fornoni A**, F. Cornacchia, N. Bellotti, G. Fasoli, A. Foschi, I. Mazzucchelli, T. Mazzullo, L. Semeraro and A. Dal Canton, Cyclosporine Induces Different Responses in Human Epithelial, Endothelial and Fibroblast Cell Cultures, *Kidney International*, 58:123-130, 2000
75. Esposito, C, Fasoli, G **Fornoni A**, F. Cornacchia, N. Bellotti, A. Foschi, T. Mazzullo, L. Semeraro, M. Maestri and A. Dal Canton, Cyclosporine A Inhibits Cell Growth and Induces Apoptosis in Porcine and Human Renal Tubular Cells. *Haematologica*, 83:74-75,1998
76. Libetta, C, T. Rampino, C. Esposito, A. Fornoni, L. Semeraro and A. Dal Canton, Stimulation of Hepatocyte Growth Factor in Human Acute Renal Failure, *Nephron*, 80:41-45, 1998
77. Dal Canton, A., **Fornoni A**, G.L. Fasoli, A. Ranghino and L. Semeraro, Volume Dependent Factors in Hypertension in Chronic Renal Failure, *Contribution to Nephrology*, 119:26-30, 1996
78. Fasoli, G.L., **Fornoni A**, L. Semeraro and C. Esposito, Implicazioni Pneumologiche nel Trapianto Renale, *Pneumologia e trapiantologia*, 106-111, Pavia, 1996
79. Dal Canton, A., C. Libetta, T. Rampino, C. Esposito, **Fornoni A** and L. Semeraro, Multiorgan Crosstalk after Acute Tissue Damage: the Case of Hepatic Growth Factor and Acute Renal Failure, *Proceedings 4rd Taormina Course of Nephrology*: 109-110, Cosenza, 1996
80. Fasoli, G.L., L. Semeraro, A. **Fornoni** and A. Dal Canton, La Nefropatia Diabetica, *Seminari di aggiornamento in Medicina Interna*, 79-86, Pavia, 1995
81. Dal Canton, A. and **A. Fornoni**, Adhesion molecules, *Proceedings 3rd Taormina Course of Nephrology*, 93-97, Cosenza, 1994

## 20. Other Works, Publications, and Abstracts

1. Correa-Medina M, Rampersaud E, Pedigo C, Nair V, Morales XA, Kretzler M, Nelson RG, Merscher S and Fornoni A. Personalized podocyte biology for the prediction of diabetic kidney disease. American Society of Nephrology (ASN) meeting; Philadelphia, PA. 2014. Poster presentation.
2. Correa-Medina M, Rampersaud E, Pedigo C, Nair V, Morales XA, Kretzler M, Nelson RG, Merscher S and Fornoni A. A New Method to Identify Podocyte-specific Gene Expression Profiles Associated with Progression of DKD in type 2 diabetes. American Diabetes Association (ADA) 74th Scientific Session; 2014. Oral Presentation
3. Correa-Medina M, Rampersaud E, Pedigo C, Nair V, Leak-Johnson T, Morales XA, Kretzler M, Nelson RG, Merscher S and Fornoni A. A non-invasive approach to predict the progression of diabetic kidney disease. European Diabetic Nephropathy Study Group; London, United Kingdom. 2014. Oral Presentation
4. Pedigo C, Mendez A, Kretzler M, Nelson RG, Burke GW, **Fornoni A**, Merscher S. TNFa affects lipid content in podocytes in diabetic kidney disease. Kern Lipid Conference 2014, Poster Presentation
5. Pedigo C, Mendez A, Kretzler M, Nelson RG, Burke GW, **Fornoni A**, Merscher S.

Infliximab protects podocytes in diabetic kidney disease. 10th International Podocyte Conference 2014, [Poster Presentation](#)

6. Pedigo C, Merscher-Gomez S, Mendez A, Kretzler M, Nelson RG, Burke GW, **Fornoni A**. TNF $\alpha$  causes podocyte cholesterol accumulation and apoptosis in diabetic kidney disease. American Society of Nephrology 2013, [Poster Presentation](#)
7. Gipson D, Troost J, Song P, Holzman LB, Sedor J, Cattran D, Fervenza F, **Fornoni A**, Kopp J, Gadegbeku C, Adler S, Trachtman H, Nachman P, Neu A, Sethna C, Kaskel F, Nelson P, Lemley K, Greenbaum L, Appel G, Lafayette R, Perumal K, Sambandam K, Barisoni L, Nast C, Kretzler M. Nephrotic Syndrome Study Network Baseline Characteristics. American Society of Nephrology 2013, [Poster Presentation](#).
8. Chang, WG, **Fornoni A**, Pober JS. Tissue engineering microvessels to perfuse isolated glomeruli *in vivo*. American Society of Nephrology 2013, [Poster Presentation](#)
9. Yoo TH, Guzman J, Mitrofanova A, Correa M, Wei C, Villarreal R, Pedigo CE, Faul C, Reiser J, Burke GW, Kretzler M, Lehto M, Groop PH, Merscher-Gomez SM, and **Fornoni A**. SMPDL3b expression determines differential suPAR-mediated podocyte injury in FSGS and DKD. American Society of Nephrology 2013, [Poster Presentation](#)
10. Merscher-Gomez S, Guzman J, Lehto M, Aguillon Prada R, Mendez A, Lassenius M, Forsblom C, Yoo T, Pedigo C, Villarreal R, Maiguel D, Johnson K, Goldberg R, Nair V, Randolph A, Kretzler M, Nelson RG, Burke GW, Groop PH, and **Fornoni, A**. Cyclodextrin protects podocytes in diabetic kidney disease (DKD). CANEsearch Meeting Miami, 2013, [Poster Presentation](#)
11. Burke GW, **Fornoni A**, Sageshima J, Chen L, Ciancio G, Chandar J, Seeherunvong W, Abitbol C, Zilleruelo G, Mattiazzi A, Guerra G, Kupin W, Roth D, Reiser J, and Mundel P. Abatacept treatment of recurrent proteinuria following kidney transplantation for focal segmental glomerulosclerosis. European Transplant Society Meeting, Nice 2012, [Poster Presentation](#).
12. Merscher-Gomez S, Aguillon Prada R, Guzman J, Yoo T, Pedigo C, Lassenius M, Lehto M, Mendez A, Rothblat GH, Sankaranarayanan S, Kretzler M, Nelson RG, Burke GW, Groop PH, and **Fornoni, A**. Cyclodextrin protects podocyte function in experimental diabetic kidney disease (DKD). American Society of Nephrology 2012, [Poster Presentation](#)
13. Yoo TH, Wei C, Villarreal R, Pedigo C, Guzman J, Faul C, Reiser J, Burke GW, Merscher-Gomez S, and **Fornoni A**. Sphingomyelin phosphodiesterase-like 3b (SMPDL3b) affects  $\beta$ 3 integrin signaling in podocytes. American Society of Nephrology 2012, [Poster Presentation](#)
14. Merscher-Gomez S, Yoo TH, Lehto M, Guzman J, Villarreal R, Lassenius M, Groop PH, **Fornoni A**. SMPDL3b, a susceptibility factor for Podocyte Malfunction in Diabetic Kidney Disease. European Diabetic Nephropathy Study Group, 2012. [Oral Presentation](#)
15. Villarreal R, Jeon J, Grahammer F, Leibiger IB, Molano RD, Guzman J, Fachado A, Yoo TH, Merscher-Gomez S, Gadea Y, Zahr-Akrawi E, Lopez-Cabezas M, Burke GW, Berggren PO, Huber TB, **Fornoni A**. Neph1 and Neph1 deficiency negatively affects pancreatic beta cell function and autocrine insulin signaling. 9th International Podocyte Conference, Miami, 2012. [Poster presentation](#).
16. Yoo TH, Wie C, Villarreal R, Guzman J, Faul C, Reiser J, Burke GW, Merscher-Gomez S, **Fornoni A**. SMPDL3b interferes with urokinase-type plasminogen activator receptor

- (uPAR) dependent signaling in podocytes. 9th International Podocyte Conference, Miami, 2012. [Poster presentation](#).
17. Schell C, Grahammer F, Schneider S, Bregenzer A, Kind J, Meyer C, Volker L, Wiech T, Kerjaschki D, Waltz G, **Fornoni A**, Huber TB. The slit revisited: analyzing the two major slit diaphragm components NEPH1 and NEPHRIN using a conditional knockout strategy. 9th International Podocyte Conference, Miami, 2012. [Poster presentation](#).
  18. Kistler AD, Caicedo A, Abdulreda MH, Yoo TH, Kerjaschki D, Quaggin SE, Berggren PO, Reiser J, **Fornoni A**. An eye-catching view of the glomerulus:non-invasive imaging of glomeruli transplanted into the anterior chamber of the mouse eye. 9th International Podocyte Conference, Miami, 2012. [Poster presentation](#).
  19. Guzman J, Jauregui A, Merscher-Gomez S, Muresan C, Aljure O, Diez-Sanpedro A, Szust J, Yoo TH, Villarreal R, Molano RD, Reiser J, Schiffer M, Kahn B, Burke GW, Abel D, Brosius FC, **Fornoni A**. GLUT4 is a direct modulator of podocyte function. 9th International Podocyte Conference, Miami, 2012. [Poster presentation](#).
  20. Jeon J, **Fornoni A**. Nephtrin effect on glucose stimulated insulin release depends on dynamin-mediated nephtrin phosphorylation. CTS-IXA, 2011, [Oral presentation](#)
  21. **Fornoni A**, George W Burke. Prevention of Post-Transplant Proteinuria: Possible Role of Rituximab. CTS-IXA, 2011, [Oral presentation](#)
  22. Merscher-Gomez S, Aguillon Prada R, Guzman J, Lehto M, Groop, PH, **Fornoni A** A circulating factor in patients with diabetic nephropathy causes podocyte insulin resistance, cytoskeleton remodeling and susceptibility to apoptosis. American Diabetes Association, 2011. [Oral Presentation](#)
  23. Aguillon Prada R, Guzman J, Lehto M, Groop, PH, Merscher Gomez S, **Fornoni A**. A circulating factor affects podocyte function in diabetic nephropathy. European Diabetic Nephropathy Study Group, 2011. [Oral Presentation](#)
  24. Merscher Gomez S, Aguillon Prada R, Guzman J, Lehto M, Groop, PH, **Fornoni A**. Podocytes are affected by a serum derived factor in diabetic nephropathy. American diabetes association 2011, [Oral presentation](#)
  25. Guzman J, Jauregui A, Walter B, Muresan C, Donnelly M, Campbell K, Szust J, Kahn B, Mundel P, Reiser J, Merscher-Gomez S, Muresan C, **Fornoni A**. Podocyte specific GLUT4 deletion protects from the development of lipopolysaccharide (LPS) induced albuminuria. American Society of Nephrology 2011, [Poster Presentation](#)
  26. Jauregui A, Aljure O, Diez-Sanpedro A, Fornoni A. GLUT4 and GLUT1 effects on podocyte function are glucose uptake independent. European Diabetic Nephropathy Study Group, 2010. [Oral Presentation](#)
  27. Sagheshima J, **Fornoni A**, Wei C, Saenz M, Li J, Mattiazzi A, Ladino M, Kamalaveni P, Ricordi C, Rastaldi MP, Mundel P, Reiser J and Burke III GW. Rituximab may decrease the incidence of FSGS recurrence after kidney transplantation by preventing down-regulation of sphingomyelinase-like phosphodiesterase 3b-precursor in podocytes. American Transplant Society 2010, [Oral presentation](#)
  28. Sagheshima J, **Fornoni A**, Wei C, Saenz M, Li J, Mattiazzi A, Ladino M, Kamalaveni P, Ricordi C, Rastaldi MP, Mundel P, Reiser J and Burke III GW. Rituximab prevents recurrent

FSGS after kidney transplantation and modulates sphingomyelinase-like phosphodiesterase 3b-precursor in podocytes. International Congress of the Transplantation Society 2010, [Oral presentation](#)

29. Jeon J, Berggren PO, Ricordi C, Mundel P, **Fornoni A**. Nephrin mediates dynamin positive effect on insulin secretion. [Featured poster presentation](#), American diabetes association 2010.
30. Pileggi A, Ribeiro MM, Hogan AR, Molano RD, Embury J, Cobianchi L, Ichii H, Inverardi L, **Fornoni A**, Ricordi, C and Pastori RL. Islet functional impairment and molecular changes following pancreas cold preservation. American Transplant Society 2009. [Oral presentation](#)
31. **Fornoni A**, Ijaz A, Jauregui A. Inhibition of JNK improves insulin sensitivity but worsens albuminuria in experimental diabetes. European Diabetic Nephropathy Study Group, 2009. [Oral Presentation](#)
32. **Fornoni A**, Sagheshima J, Wei C, Saenz M, Li J, Mattiazzi A, Ladino M, Kamalaveni P, Ricordi C, Rastaldi MP, Mundel P, Reiser J and Burke III GW. Effect of Rituximab on the regulation of sphingomyelinase-like phosphodiesterase 3b-precursor in recurrent FSGS. American Society of Nephrology 2009, [oral presentation](#).
33. **Fornoni A**, Jeon J, Varona-Santos JL, Cobianchi L, Aljure O, Jauregui A, Mandic SA, Bark C, Johnson K, McNamara G, Pileggi A, Molano RD, Reiser J, Tryggvason K, Kerjaschki D, Berggren PO, Mundel P and Ricordi C.. Nephrin is expressed in human pancreas on the surface of insulin vesicles and is essential for glucose stimulated insulin release. American Society of Nephrology 2009, [Poster Presentation](#)
34. Ijaz A, Tejada T, Catanuto P, Varona Santos J, Xia X, Sanchez P, Sanabria N, Lenz O, Elliot SJ, **Fornoni A**. Failure to phosphorylate AKT in podocytes from diabetic mice with early nephropathy promotes cell death. European Consortium on Diabetic Nephropathy, 2008. [Oral Presentation](#)
35. Sagheshima J, Ciancio G, **Fornoni A**, Chen L, Abitbol C, Chandar J, Kupin W, Guerra G, Roth D, Shariatmadar S, Zilleruelo G, Burke G III. Rituximab Induction in High Risk Kidney Transplant Recipients May Decrease the Incidence and Severity of Recurrence of Focal Segmental Glomerulosclerosis. American Transplant Society, 2008. [Oral Presentation](#)
36. Varona-Santos J, Pileggi A, Molano RD, Sanabria N, Zhar E Ijaz A, Ichii H, Pastori RL, Inverardi L, Ricordi C, **Fornoni A**. Lack of JNK1, but not JNK2 facilitates pancreatic islet function, viability and graft survival after transplantation. American Diabetes Association, 2008. [Poster presentation](#)
37. Ijaz A, Tejada T, Catanuto P, Xia X, Elliot SJ, Lenz O, Jauregui A, Molano RD and **Fornoni A**, c-Jun N Terminal Kinase inhibition improves insulin sensitivity but does not prevent albuminuria in experimental diabetes, American Society of Nephrology 2008, [Poster Presentation](#)
38. Ijaz A, Tejada T, Catanuto P, Xia X, Elliot SJ, Lenz O, Jauregui A, Molano RD and **Fornoni A**. Insulin potentiates TRPC6 expression in diabetic podocytes, but TRPC6 blockade induces cell death. American Society of Nephrology 2008, [Poster Presentation](#).
39. Tejada T, Xia X, Sanchez P, Punjabi O, Lenz O, Elliot SJ, **Fornoni A**. Glomerular down-regulation of AKT characterizes the early phases of diabetic nephropathy in db/db mice

and is associated with decreased podocyte survival. Journal of the American Society of Nephrology 2007. [Poster presentation](#).

40. Cobianchi L, **Fornoni A**, Pileggi A, Molano DR, Inverardi L. Inhibition of MAPK p-38 by riboflavin in islet cells. American transplant Society, 2007. [Poster Presentation](#).
41. Yamamoto T, Ricordi C, Miki A, Sakuma Y, Mita A, Molano DR, **Fornoni A**, Pileggi A, Inverardi L and Ichii H.  $\beta$ -cell-Specific Cytoprotection by Prolactin on Human Islets. International Pediatric Transplant Association, 2007. [Poster presentation](#)
42. Tejada T, Xia X, Sanchez P, Elliot SJ, Lenz O, **Fornoni A**. High Serum and Urine Concentration of Inflammatory Biomarkers Precedes the Onset of Microalbuminuria in db/db Mice. American Society of Nephrology, 2006. [Poster presentation](#)
43. Lenz O, **Fornoni A**. Management of Anemia and Secondary Hyperparathyroidism by Family Medicine and Internal Medicine Trainees. American Society of Nephrology, 2006. [Poster presentation](#)
44. Lenz O, **Fornoni A**. Blood Pressure Management by Family Medicine and Internal Medicine Trainees in Patients with Chronic Kidney Disease. American Society of Nephrology, 2006. [Poster presentation](#)
45. Contreras G, Pardo V, Lenz O, Mercado C, Choi K, **Fornoni A**, Krishnamurthy G, Blake R, Carvalho C, Castro M, Jaraba I. Comparison of Patients with Segmental vs Global Class IV Lupus Nephritis. American Society of Nephrology, 2006. [Poster presentation](#)
46. Tejada T, Xia X, Sanchez P, Elliot SJ, Lenz O, **Fornoni A** Glomerular Down-Regulation of PKB/AKT Precedes the Onset of Significant Albuminuria in db/db Mice. American Society of Nephrology, 2006. [Poster presentation](#)
47. **Fornoni A**, Roth D and Lenz O, Identification of Rapid Progressors May Facilitate Timely Access Placement in Patients with Chronic Kidney Disease Stage 4 and 5, National Kidney Foundation, 2005. [Poster presentation](#)
48. Sadhu S, **Fornoni A**, Lenz O. High Prevalence of Central Venous Catheters in Patients Starting Hemodialysis Does Not Indicate Failure of CKD Clinics. American Society of Nephrology 2005. [Poster presentation](#)
49. Lenz O, **Fornoni A**, Striker LJ, Striker GE. Dinucleotide Repeat Expansion and Clonal Selection in the Pathogenesis of Diabetic Nephropathy. Journal of the American Society of Nephrology, 2003. [Poster presentation](#)
50. **Fornoni A**, Elliot SJ, Rosenzweig S, Rivera A, Lenz O, Striker GE, Striker LJ. Low IGFBP-2 Expression Is Responsible for Increased IGF-I Pathway Activation in Mesangial Cells from Glomerulosclerosis Prone ROP Mice. American Society of Nephrology, 2003. [Poster presentation](#)
51. **Fornoni A**, Lenz O, Banerjee A., Striker GE, Striker LJ. Dinucleotide Repeat Expansion and Clonal Selection of Mesangial Cells in Diabetic Nephropathy. American Society of Human Genetics, 2002. [Poster presentation](#)
52. **Fornoni A**, Lenz O, Banerjee A, Striker GE, Striker LJ. Dinucleotide Repeat Instability and Clonal Selection in Diabetic Nephropathy. American Society of Nephrology, 2002. [Oral presentation](#)

53. **Fornoni A**, Zheng F, Striker GE, Striker LJ. The Genetic Background Determines the Reversibility of Changes Induced by High Glucose in Murine Mesangial Cells. American Diabetes Association, 2001. [Poster presentation](#)
54. Zheng F, **Fornoni A**, Elliot SJ, Guan YF, Breyed MD, Striker LJ, Striker GE. PPAR $\gamma$  Activation Suppresses TGF- $\beta$  Mediated Type I Collagen Expression in Mesangial Cells. American Diabetes Association, 2001. [Presidents' Poster Presentation](#)
55. **Fornoni A**, Lenz O, Wang Y, Potier M, Striker LJ, Striker GE. A Shorter MMP-9 Promoter Characterizes a Mouse Strain Susceptible to Glomerulosclerosis. American Society of Human Genetics, 2001. [Poster presentation](#)
56. **Fornoni A**, Striker GE, Striker LJ. Hepatocyte Growth Factor, but not Insulin-like Growth Factor I, Protects Podocytes from Cyclosporin A Induced Apoptosis. American Society of Nephrology, 2000. [Poster presentation](#)
57. **Fornoni A**, Rosenzweig SA, Elliot JS, Striker GE, Striker LJ. 17- $\beta$  estradiol Affects IGF-I Receptor Numbers and IGFBP-2 Production in Murine Mesangial Cells. American Society of Nephrology, 2000. [Poster presentation](#)
58. **Fornoni A**, Striker GE, Striker LJ. Phenotype changes Induced by High Glucose Concentrations are Reversible Only in Mesangial Cells from Sclerosis-Resistant Mice. American Society of Nephrology, 2000. [Poster presentation](#)
59. Potier M, **Fornoni A**, Salas J, Lenz O, Karl M, Elliot SJ, Striker GE, Striker LJ. Estrogen and renal disease in aging women. Endocrine Society, 1999. [Poster presentation](#)
60. **Fornoni A**, Lenz O, Elliot SJ, Striker GE, Striker LJ. Cyclosporin A determines extracellular matrix accumulation in mesangial cells isolated from sclerosis-prone but not sclerosis-resistant mice. JASN (10), A3271, 1999. [Oral presentation](#)
61. **Fornoni A**, Rosenzweig SA, Elliot SJ, Lenz O, Striker GE, Striker LJ. Mesangial cells isolated from sclerosis-prone (ROP) mice and sclerosis-resistant (C57) mice have different extracellular matrix turnover regulation. American Society of Nephrology, 1999. [Poster presentation](#).
62. **Fornoni A**, Lenz O, Elliot SJ, Striker GE, Striker LJ. Cyclosporin A toxicity on podocytes is characterized by apoptosis and decreased MMP-2 activity. American Society of Nephrology, 1999. [Poster presentation](#).
63. **Fornoni A**, Elliot JS, Rosenzweig SA, Lenz O, Striker GE, Striker LJ. High glucose levels have different effects on extracellular matrix turnover in mesangial cells isolated from sclerosis-prone and sclerosis-resistant mice. American Society of Nephrology, 1999. [Poster presentation](#)
64. Lenz O, **Fornoni A**, Elliot SJ, Striker GE, Striker LJ. Estrogen increases MMP-2 expression and decreases collagen type I synthesis in glomerular epithelial cells in high ambient glucose. American Society of Nephrology, 1999. [Poster presentation](#)
65. **Fornoni A**, Howard GA, Roos BA, Elliot SJ, Striker GE, Striker LJ. Cyclosporin A Treatment affects extracellular matrix synthesis and degradation by mouse osteoblasts in vitro. American Society of Nephrology, 1999. [Poster presentation](#)

66. Potier M, **Fornoni A**, Lenz O, Karl M, Elliot SJ, Striker GE, Striker LJ. 17 $\beta$ -Estradiol differentially regulates MMP-2 activity and mRNA expression in mouse mesangial cells with a different genetic background. American Society of Nephrology, 1999. [Poster presentation](#)
67. Potier M, **Fornoni A**, Lenz O, Karl M, Elliot SJ, Striker GE, Striker LJ. Estrogen regulates MMP-2 activity in human mesangial cells expressing ER $\alpha$  mRNA. American Society of Nephrology, 1999. [Poster presentation](#)
68. Esposito C, **Fornoni A**, Cornacchia F, Fasoli G, Bellotti N, Foschi A, Fossati L, Mazzullo T, Semeraro L, Dal Canton A. Cyclosporine A inhibits endothelial cell growth and counteracts HGF mitogenic effect. American Society of Nephrology, 1998. [Poster presentation](#)
69. Esposito C, **Fornoni A**, Cornacchia F, Fasoli G, Bellotti N, Foschi A, Mazzullo T, Semeraro L, Dal Canton A. Cyclosporine A (CsA) antiproliferative/toxic effect is mediated by the induction of NO and apoptosis in human renal epithelial cells (HK-2) but not in human microvascular endothelial cells (HEC). American Society of Nephrology, 1998. [Poster presentation](#)
70. Esposito C, Fasoli G, **Fornoni A**, Bellotti N, Mazzucchelli I, Mazzullo T, Foschi A, Cornacchia F, Semeraro L, Dal Canton A. Long-term exposure to high glucose primarily alters endothelial cell adhesiveness to PBMCs. American Society of Nephrology, 1998. [Poster presentation](#)
71. Esposito C, Fasoli G, **Fornoni A**, Fossati G, Guallini P, Maestri M, Bellotti N, Semeraro L, Dal Canton A. Cyclosporine A (CsA) inhibits cell growth and induces apoptosis in porcine renal tubular cell culture. European Dialysis and Transplant Association, 1997. [Poster presentation](#)
72. Esposito C, Bellotti N, Semeraro L, Soccio G, Klersy C, Fasoli G, **Fornoni A**, Sozze' E, Campana C, Gavazzi A, Dal Canton A. Risk factors of chronic renal failure in heart transplanted patients. European Dialysis and Transplant Association, 1997. [Poster presentation](#)
73. Gaspari A, Ballestreri M, DeLeo A, Noli S, Passalia L, Bolla E, Matteotti C, **Fornoni A**, Fasoli G, Dionigi P, Bellinzona G, Maestri M, Zonta A. Impiego sperimentale dell' IGF-1 nel trapianto renale: effetti emodinamici. Proc. XXIV Congresso nazionale Societa' Italiana trapianti d' Organo. 1997. [Oral presentation](#)
74. Maestri M, Rademacher L, Passalia L, Gaspari A, Noli S, Matteotti C, Luzzana F, Innocente F, Bolla E, Polese M, Scotti A, Esposito C, **Fornoni A**, Dionigi P, Zonta A. L' insulin-like growth factor-1: effetti sul trapianto pancreatico fetale. XV Riunione annuale clinico scientifica del Dipartimento di Chirurgia. Pavia, 1997. [Oral presentation](#)
75. Esposito C, Bellotti N, Semeraro L, Soccio G, Klersy C, Fasoli G, **Fornoni A**, Sozze' E, Campana C, Gavazzi A, Dal Canton A. Risk factors of chronic renal failure in heart transplanted patients. American Society of Nephrology, 1997. [Oral presentation](#)
76. Rampino T, Libetta L, **Fornoni A**, Semeraro L, Dal Canton A. Role of hepatic growth factor (HGF) in acute renal failure (ARF). European Dialysis and Transplant Association, 1996. [Poster presentation](#)
77. Fasoli G, **Fornoni A**, Esposito C. Implicazioni pneumologiche nel trapianto renale. Congresso nazionale Pneumologia e Trapiantologia, Pavia 1996. [Poster presentation](#)

78. Dal Canton A, Fossati G, **Fornoni A**, Mazzucchelli I, Mazzone A, Ricevuti G, Meyrier A. Expression of intercellular adhesion molecule-1 (ICAM-1) in minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). European Dialysis and Transplant Association, 1995. Poster presentation.

## V. PROFESSIONAL

### Current funding:

#### 1R01DK090316-01A1 (NIH/NIDDK)

Role: PI

09/30/11-07/30/16

Title: Novel Targets of Rituximab in FSGS

Amount awarded (total): \$ 1,600,000

#### 5-U54-DK083912-3 (NIH/NIDDK)

Role: Local PI (Matthias Kretzler PI)

09/08/09 - 06/30/19

Title: Nephrotic Syndrome Rare Diseases Clinical Research Network

Amount awarded: \$ 897,428/year

#### 5UM1DK100846-02 (NIH/NIDDK)

Role: Local PI (Lawrence Holtzman PI)

06/01/13-05/30/18

Title: The Primary Outcome of Glomerulonephritis Study.

Amount awarded (total): \$ 550,000

#### DCC/NIH (U24DK076169-08)

Role: PI

09/01/14-08/30/15

Title: Clinical Development of Hydroxy-propyl-beta cyclodextrin in DKD

Amount awarded (total): \$ 59,299

#### UL1TR000460 (NCATS/NIMHD)

Role: Co-I (Jose Szapocznik PI)

06/01/12-05/31/17

Title: Miami Clinical Translational Science Institute

Amount awarded (total): \$ 17,200,000

#### Hoffman-La Roche

Role: PI

11/01/14-01/30/18

Title: Targeting cholesterol efflux from podocytes in rare kidney diseases

Amount Requested \$ 1,285,740

#### Hoffman-La Roche

Role: PI

11/01/14-01/30/18

Title: Targeting DDR1 in Alport Syndrome

Amount Requested \$ 1,900,000

### Awarded/declined funding:



1R03DK091636-01 (NIH/NIDDK)

Role: PI

12/01/11-11/30/13 (score 20, not awarded because of R01 award)

Title: Role of Nephrin deficiency in the mouse pancreas

Amount requested: \$ 100,000

**Pending funding:**

R01 AN:3742523 (NIH/NIDDK)

Role: PI

07/01/15-06/30/20

Title: SMPDL3b and IR signaling

Amount requested: 2,392,777

1R01DK104753-01 (NIH/NIDDK)

Role: PI

04/01/15-03/31/20

Title: Cellular Cholesterol and Podocyte Function in Diabetic Kidney Disease

Amount requested: 2,864,302

R01 AN:3741737 (NIH/NIDDK)

Role: Co-Investigator (PI: Sandra Merscher)

07/01/15-06/30/20

Title: The role of TNF alpha in podocyte injury in FSGS

Amount requested: 2,449,658

AHAB I

Role: PI

Title: Cellular lipids and podocyte function in DKD

Amount requested: \$660,000

Akros Pharma

Role: PI

Title: Development of assays for drug discovery

Amount Requested \$ 850,000

**Completed Funded Research:**

4-2004-361 (Ricordi)

12/01/03-11/30/08

JDRFI

\$1,150,000

JDRF Center for Islet Transplantation at the University of Miami – Diabetes Research Institute

Role: PI Pilot #5

Effort: 20%

12/1/05-11/30/07

Amount awarded: \$ 55,000

Title: Role of JNK1 and JNK2 in experimental islets transplantation

Stanley J. Glaser Foundation Biomedical Research Support Grant

Role: PI

Effort: 5%

02/15/06-02/14/07

Amount awarded: \$ 25,000  
Title: C-jun terminal kinase (JNK) inhibition improves human islet function, viability and graft survival

Amgen Junior Faculty award

Role: PI  
Effort: N/A  
01/07/06-10/30/09  
Amount awarded: \$ 120,000  
Title: Role of JNK in diabetic nephropathy

Scientific Award Committee Award

Role: PI  
Effort: N/A  
08/01/05-07/31/06  
Title: Hepathopancreatic transdifferentiation  
Amount awarded: \$ 12,000

Scientific Award Committee Award

Role: PI  
Effort: N/A  
08/01/09-07/31/10  
Title: Rituximab and podocyte function in recurrent FSGS  
Amount awarded: \$ 20,000

KDK082636A (NIH)

Role: PI  
07/01/09-06/30/12  
Title: Role of Nephtrin in beta cell function  
Amount awarded: \$ 372,600

ADA Junior Faculty Award

Role: PI  
07/01/09-06/30/12  
Title: Role of nephtrin in insulin secretion  
Amount awarded: \$ 414,000

DK70341 (NIH/NIDDK)

Role: Local PI (Howard Trachtman PI)  
3/01/05 - 02/28/13  
Title: Novel therapies for focal segmental glomerulosclerosis

Nephcure Foundation

Role: PI  
10/01/11-09/30/12  
Title: Rituximab affects podocyte lipids in FSGS  
Amount awarded: \$ 50,000

Scientific Award Committee Institutional Award

Role: PI  
06/01/12-12/30/13  
Title: Development of a cell-based assay for the prediction of proteinuria in FSGS  
Amount awarded: \$ 20,000

DCC/NIH (U24DK076169-08)

Role: PI

07/01/13 – 06/30/14

Title: Role of Podocyte Lipids in the Prediction of Diabetic Nephropathy

Amount awarded: \$ 100,000

1UL1TR000460 (CTSA Miami Clinical and Translational Science Institute/NIH)

Role: PI of Pilot Project (Jose Szapocznik PI)

01/07/2013-12/31/2013

Title: Personalized podocyte biology for the prediction of diabetic kidney disease in high risk populations

Amount awarded: \$ 100,000

DRIF (Diabetes Research Institute Foundation)

Role: Co-PI

06/01/13 – 05/30/14

Title: Lypotoxicity and autoimmunity in Type 1 Diabetes

Amount awarded: \$ 100,000

AHA

Role: sponsor (PI: Rodrigo Villarreal)

07/01/2012-06/30/2014

Title: Role of nephrin deficiency in the mouse pancreas

Amount awarded: \$ 98,264

**23. Editorial Responsibilities:**

Invited reviewer for the following scientific journals:

- Journal of Clinical Investigation
- PNAS
- Diabetes
- Journal of the American Society of Nephrology
- American Journal of Transplantation
- Kidney International
- Cell Transplantation
- Endocrinology
- Journal of Cellular and Molecular Medicine
- Journal of Medical case reports
- Metabolism
- American Journal of Hypertension
- Journal of clinical case report
- American Journal of Nephrology
- American Journal of Pathology
- Gender Medicine
- PLoS ONE
- International Journal of Nephrology
- Clinical and Experimental Medicine
- Diabetic Medicine
- Clinical therapeutics
- Case Reports in Nephrology and Urology
- American Journal of Physiology
- Clinical Science
- Hemodialysis International
- Nephrology, Dialysis and Transplantation

- World Journal of Nephrology
- Pediatric Nephrology
- European Journal of Internal Medicine
- Case reports in Nephrology and Urology
- World Journal of Diabetes
- Molecular and Cellular Endocrinology
- Journal of Nephrology

Editorial board member (or guest editor) of

- Diabetes (2013-present)
- Current Diabetes Review (guest editor 2011)
- World Journal of Diabetes
- Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
- Journal of Nephrology & Therapeutics
- Frontiers in Endocrinology (guest editor 2014)
- Current Diabetes Reviews (guest editor 2014)

Others

- Invited Reviewer for American Heart Association Grant applications (2009-present)
- Invitation to become Editor in Chief of the International Journal of Nephrology (2008-declined to facilitate research focus)
- Reviewer for UK Diabetes Grant applications (2009-present)
- Reviewer for American Diabetes Association abstract selection (2009-present)
- Reviewer for American Society of Nephrology abstract selection (2007-present)
- Chair “diabetic nephropathy mechanisms”, ASN 2010
- Chair “new experimental models of DN”, EDNSG 2011
- Chair “diabetic nephropathy: basic” poster tour, ADA 2011
- Reviewer for the Swiss National Science Foundation (2011-present)
- Reviewer for the Cariplo Foundation (2011-present)
- Reviewer for the India Alliance Fellowship (2011-present)
- Reviewer for the American Heart Association (2010-present)
- Reviewer for the American Diabetes Association (2011-present)
- Chair: “Tissue Repair”, CTS-IXA Joint Congress 2011
- Ad hoc reviewer for NIH “Pathobiology of kidney disease” study session June 2012
- Ad hoc reviewer for NIH ZDK1 GRB1 “Ancillary studies Review” study session April 13
- Ad hoc reviewer for NIH ZRG1 DKUS-E “Kidney and Urology, member conflict” study session, March 2013
- Glomerular Diseases Advisory Group for the American Society of Nephrology (2014-2017)
- Italian Ministry of Health, Grant reviewer (2014-present)
- Oak Ridge Associate Universities Grant Reviewer (2014-present)
- Ad hoc reviewer for NIH ZRG1 DKUS-A “Kidney and Urology, member conflict” study session, Jan 2015
- 

**24. Professional and Honorary Organizations:**

1999-2002	Endocrine Society
2000-2003	American Society of Human Genetics
2001-present	American Society of Nephrology
2005-present	American Diabetes Association
2005-present	Woman in Nephrology
2008-present	European Consortium for Diabetic Nephropathy
2008-present	National Kidney Foundation

## 25. Honors and Awards

- 1989 Merit Fellow, University College “Collegio Nuovo” 1990 Winner of an I.F.M.S.A. (International Federation of Medical Students Associations) grant to spend a 2-month fellowship in the Dept. of Internal Medicine, University Hospital of Iasi, Rumania
- 1993 Winner of an I.F.M.S.A. grant to spend a 1-month fellowship in the Department of Pulmonary Medicine, University Hospital of Lisbon, Portugal
- 1994 Winner of an I.F.M.S.A. grant to spend a 1-month fellowship in the Department of Nephrology, University Hospital of Helsinki, Finland
- 2003 Resident Scholarly Activity Program Award, University of Miami School of Medicine
- 2004 Travel award, Professional Development Course (basic), American Society of Nephrology
- 2005 Scientific Award Committee Award for the project “Hepatopancreatic transdifferentiation”
- 2006 Stanley J. Glaser Foundation Biomedical Research Award, University of Miami
- 2006 Fellow, American Society of Nephrology
- 2008 Travel award, Professional Development Course (advanced), American Society of Nephrology
- 2009 Scientific Award Committee Award for the project “Rituximab and podocyte function in recurrent FSGS”
- 2012 Scientific Award Committee Award for the project “Development of a cell-based assay for the prediction of proteinuria in FSGS”
- 2013 Endowed Chair, Peggy and Harold Family Katz Drug Discovery Center

## 26. Post Doctoral Fellowships

- 04/1998-04/2001 **Research Fellow**, Renal Cell Biology Laboratory, University of Miami.  
Mentors: Liliane J. Striker, MD and Gary E. Striker, MD.

## 27. Other Professional Activities:

### *Multicenter Clinical trials*

- NEPTUNE Steering Committee (Miami PI)
- Questcor Pharmaceuticals, Acthar and Diabetic Nephropathy Trial (Miami PI)
- FONT II (Miami PI)
- UM1-Progress/CureGN (Miami, PI)
- Duet (Miami PI)

### *Consultant*

- Mesoblast
- Roche
- Kunming Biomed International
- Bristol Mayer Squibb
- Abbvie
- Genentech

### *Filed patents*

- PCT/US11/56272: Assays, Methods and Kits for Predicting renal disease and personalized treatment strategies.
- PCT/US2012/062594: Soluble Urokinase Receptor (suPAR) in Diabetic Kidney Disease.
- PCT/US13/36484: method of using cyclodextrin

## VI. TEACHING

**28. Teaching awards:** none

**29. Teaching Specialization:**

10/1995-04/1998: I was teaching small groups of medical students during their Nephrology class how to read kidney biopsies and how to interpret urinary sediment. This experience was under the supervision of Dr. A. Dal Canton, Chairman of Nephrology at the University of Pavia, Italy. This teaching experience occupied 20 hours of my time for each academic year.

01/1999-05/2002: I trained Post Doctoral fellows and technicians in the Laboratory of Renal Cell Biology/Vascular Biology Institute directed by Dr L.J. Striker and G.E. Striker. My training involved teaching of cell biology and molecular biology techniques. I also supervised younger fellows in the process of writing their manuscripts. This teaching experience occupied 10 hours a week of my time.

07/2002-06/2004: I was involved in the training of medical students as teaching resident during my two years of residency.

2004-2008: I have been involved in teaching selected Nephrology topics to the Latin American Students of the Harrington Program at the University of Miami Miller School of Medicine.

2005-2008: I gave classes twice a year to DVR personnel on issues related to care of transgenic mice.

2005-2008: I was responsible for the Nephrology Board Review lectures for the Residency Program in Internal Medicine.

2006-2007 I've been responsible for the organization of a monthly "Translational Research Meeting" for the resident in Internal Medicine

2005-present Mechanisms of disease course: small group and lecture on "Inherited disease of the kidney".

2005-present I participate three times a week to Nephrology conferences: Journal Club, Research meeting, Pathology meeting, Renal Grand Round, Core Curriculum lectures. I'm responsible for the preparation of 3-4 yearly lectures.

2005-present I participate once a week to the Diabetes Research Institute Journal club and lab meetings

2006-2010 Responsible for a monthly research meeting for Nephrology fellows of our program.

2007-present I served as judge at the Eastern-Atlantic Student Research Forum

**CME or CME equivalent lectures**

May 2007 Medical Grand Round at Mount Sinai, Miami: "Diabetic Nephropathy"

Feb 2008 Endocrine Grand Round at the University of Miami: "Diabetic Nephropathy"

Jan 2008 "Advance in Internal Medicine" CME course "Diabetic Nephropathy"

Feb 2010 Invited speaker for the Podocyte P8 meeting "Rituximab and recurrent FSGS"

Oct 2010 Medical Grand Round at the University of Miami "Diabetic Nephropathy beyond glycemic control"

Apr 2011 Visiting Professor at Yale, Pediatric and Adult Nephrology Research Conference: "Cellular lipids: where FSGS meets DN"

May 2011 Visiting Professor at University of Alabama, Renal Grand Round: "Cellular lipids: where FSGS meets DN"

May 2011 Invited speaker for Rose Conference "Detection and management of CKD"

Sep 2011 Visiting Professor at University of Michigan, Renal Grand Round: "Lipids: do FSGS and DN have anything in common?"

Jun 2011 Invited speaker for the National American Diabetes Association Symposium: "Inflammation and diabetic nephropathy", San Diego

Nov 2011 Visiting Professor at NYU, Renal Grand Round: "Rituximab in recurrent FSGS"

Dec 2011 Visiting Professor at Yale, Renal Grand Round: "Personalized approach to kidney disease in diabetes"

Jan 2012 Visiting Professor at Ohio State University, Renal Grand Round “Sphingolipids in recurrent FSGS”

Jan 2012 Visiting Professor at Gaslini Hospital, University of Genoa, Italy. Renal Grand Round: “Rituximab, sphingolipids and FSGS”

Jan 2012 Speaker for Immune Pathology international conference: “Non immune function of immunosuppression in FSGS”

Mar 2012 Visiting Professor at Mayo Clinic, Rochester, MN, Renal Grand Round “Targeting lipids in FSGS and DKD”

Mar 2012 Visiting Professor at Mayo Clinic, Rochester, MN, Renal Research Seminar “Insulin Resistance and Diabetic Kidney Disease”

Mar 2012 Invited speaker for Omniprex conference for diabetes updates ““Diabetic Nephropathy beyond glycemic control”

Apr 2012 Invited speaker for the American Diabetes Association Regional meeting, Hollywood, FL “Management of the patient with DKD”.

Apr 2012 Invited speaker for the 9<sup>th</sup> International podocyte conference, Miami, FL : “Targeting lipids in FSGS and DKD”

Jul 2012 Visiting Professor at the Kidney Institute, Kansas University, MS, Renal Grand Round: “Novel aspects in the pathogenesis of FSGS and DKD”.

Jul 2012 Invited Speaker for the “Raising Star Program”, University of Miami: “Updates in the diagnosis and management of DKD”.

Aug 2012 Visiting Professor at UT Soutwestern, Dallas, TX. Renal Grand Round: “cellular lipids and pathogenesis of FSGS and DKD”.

Sep 2012 Endocrinology Grand Round. “Cellular Lipids and Diabetic Kidney Disease”.

Jan 2013 Roche Research Lecture: “Drug discovery in DKD”

Apr 2013 Visiting Professor at Boston University. Renal Grand Round. “Targeting Cellular Lipids in FSGS and Diabetic Nephropathy”

Apr 2013 Second International Renal Meeting and Mayo Clinic Day. Invited speaker. “Therapy of FSGS”: immunomodulation or direct effect on podocytes”.

Sep 2013 Peruvian Diabetes Association, Lima, Peru. Invited speaker. “Role of podocytes in the progression of diabetic nephropathy”.

Mar 2014 Eastern-Atlantic Student Research Forum, Awards Banquet Speaker, “Cyclodextrin, an old drug for a new indication”.

Mar 2014 Cell Biology Research Forum, Invited speaker, “Sphingolipids and podocyte function in focal and segmental glomerulosclerosis”

May 2014 Invited Speaker, Royal College of Physician, London, UK. “Key molecular mechanisms and pathways of Diabetic nephropathy for the clinician”.

May 2014 Invited Speaker, Kidney Research UK Lecture, London, UK. “Lipid biology and podocyte function in diabetic kidney disease”.

Aug 2014 Invited Speaker, 6<sup>th</sup> International Symposium on Primate Research “From Bench to Clinic”.,Kunming, China. Lecture: Key molecular mechanisms in Diabetic Nephropathy.

Sep 2014 Peruvian Diabetes Association, Lima, Peru. Invited speaker. “Podocytes insulin signaling and diabetic nephropathy”.

Sep 2014 Peruvian Diabetes Association, Lima, Peru. Invited speaker. “Podocytes lipid biology and diabetic nephropathy”.

Sep 2014 Diabetic Nephropathy Course, Lima, Peru. Invited speaker. “New Biomarkers for diabetic nephropathy”.

Sep 2014 Diabetic Nephropathy Course, Lima, Peru. Invited speaker. “New treatments for diabetic nephropathy”.

Nov 2014 Invited Speaker, American Society of Nephrology, Philadelphia. Lecture Series “Podocyte Lipid Biology in Diabetic Nephropathy”.

Nov 2014 Invited Speaker, American Society of Nephrology, Philadelphia. Symposium: Identifying Practical Targets for Podocyte-Focused Anti-Proteinuric Therapies.

Nov 2014 Invited Speaker, American Society of Nephrology, Philadelphia. Symposium: From Steroids to Rituximab: Renal Expression of Drug Targets.

### 30. Thesis and Dissertation Advising/Post-doctoral student supervision

#### **Graduate Students dissertation committee:**

2010-2013 Ansel Amaral (MD PhD student, dissertation committee)  
 2011 Michael Bellio (PhD student, Qualifying exam committee)  
 2011-present Alexis Sloan (PhD student, dissertation committee)  
 2012-present Christopher Pedigo (PhD student, mentor year 1, co-mentor in subsequent years)  
 2012 Michael Birnbaum (PhD student, Qualifying exam committee)  
 2012-present Cao Yenong (PhD student, dissertation committee)  
 2012-present Ethan Young (MD PhD student, dissertation committee)

#### **Post Doctoral student supervision record:**

Past / Current Trainee	Trainee Name (Where Training Occurred)	Training Period	Prior Academic Degree(s)	Title of Research Project	Current Position of Past Trainees / Source of Support of Current Trainees
Past	Cobianchi, Lorenzo	05-07	MD	Riboflavin and islet function	Asst. Prof. of Surgery, U. of Pavia, Italy
Past	Tejada, Thor	06-07	MD	Insulin signaling in podocytes	Cardiology Fellow at Emory, Atlanta
Past	Ramirez, Miriam	07-08	PhD	Hepatopancreatic transdifferentiation	Scientist in Private company (Spain)
Past	Santos, Javier	07-08	PhD	Nephrin in beta cell survival	Pharmacist
Past	Ijaz, Adeel	07-08	MD	JNK and diabetic nephropathy	Academic Nephrologist, Texas Health
Past	Jongmin Jeon	08-11	MS	Nephrin and beta cell function	Graduate student in Sweden, ADA/NIH
Past	Dony Maignel	12-13	PhD	Nephrin and beta cell function	Industry
Past	Tae Hyun Yoo	11-13	MD PhD	Role of SMPDL-3b in podocytes	Academic Nephrologist, Korea
Past	Guzman, Johanna	09-14	MD	Role of GLUT4 and cholesterol in podocyte function	NIH DRIF
Past	Rodrigo Villarreal	11-14	PhD	NEPH1 in pancreatic beta cells	AHA



Past / Current Trainee	Trainee Name (Where Training Occurred)	Training Period	Prior Academic Degree(s)	Title of Research Project	Current Position of Past Trainees / Source of Support of Current Trainees
Current	Christopher Pedigo	12-	MS	TNF and podocyte apoptosis	AHA
Current	Alla Mitrofanova	13-	PhD	SMPDL3b in DKD	Transplant Foundation
Current	Farah Leclercq	13-	MS	SMPDL3b and podocytes	N/A, full time volunteer
Current	Mayrin Correa	13-	MD PhD	Personalized Podocyte Biology	CTSI grant
Current	Ximena Morales	13-	MD	Podocyte lipids and Alport	N/A, full time volunteer
Current	Allison Barchi-Chung	13-	MS	Nephrotic Syndrome Rare Diseases Clinical Research Network	NIH/NIDDK
Current	Patel, Ronak Prakash	14-15	MD student	Transplant proteinuria	ASN kidney-TREKS program

## VII. SERVICES

### 31. University Committee and Administrative Responsibilities:

2005-present Objective Structured Clinical Examination for third year medical students  
2005-present Nephrology Fellows Selection Committee  
2008-present Reviewer for Stanley Glaser Award  
2008-present MD PhD Selection Committee  
07/2013-present PIBS Mentoring session, MD PhD Program.  
08/2014-present Chair, Search Committee for Cardiology Chief Division

### 32. Community Activities:

2006-present Volunteer for National Kidney Foundation  
2010-present Volunteer for NephCure